Brent Saunders returned to Bausch + Lomb in 2023 to help address unmet needs in eye care, focusing on innovation and ...
PE: How are global regulatory agencies adjusting their policies for biosimilars? Woollett: The clear leaders in the space of ...
FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies
The FDA’s approval of Uplizna for antibody-positive generalized myasthenia gravis introduces a twice-yearly CD19-targeted therapy option for the rare autoimmune condition. The FDA has approved Amgen’s ...
OTR Therapeutics Announces Collaboration with Zealand Pharma to Develop Metabolic Disease Treatments
OTR Therapeutics and Zealand Pharma collaborate to develop novel metabolic disease treatments, with a potential deal value of ...
Lilly’s first Phase III results for retatrutide show unprecedented weight loss and marked reductions in osteoarthritis pain, ...
PE: How will recent regulatory developments at FDA impact feasibility assessments in clinical planning? Woollett: It’s ...
In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the ...
DTC prescription drug models are reshaping the pharma industry by altering pricing dynamics and enhancing patient access, ...
The Trump administration has taken steps to strengthen domestic manufacturing across all industries since coming into office ...
The collaboration agreement joins Relation’s AI-powered drug discovery platform and human data generation capabilities with ...
M&A in biopharma is shaped by policy uncertainties, tariffs, and potential marketing rule changes, influencing strategic ...
TrumpRx lowers drug prices but doesn't address diagnosis and care access barriers, limiting its impact on patient outcomes. Pharma must develop DTP programs integrating education, testing, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results